SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Staff Says Use for GE Healthcare (JOBS) Imaging Drug Unclear

August 7, 2009 | 
1 min read

Bookmark and Share

Reuters -- U.S. regulatory staff, in a memo released on Friday, questioned how a GE Healthcare experimental imaging drug should be used for patients undergoing brain imaging tests to help diagnose certain disorders.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Roche's tower in Shanghai, China
Approvals
Roche Continues Regulatory Run With Acute Stroke Expansion for Heart Attack Drug
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac